Navigation Links
Validus Pharmaceuticals Now Exclusively Marketing Six Established U.S. Product Lines Purchased From Leading Healthcare Company
Date:11/19/2012

PARSIPPANY, N.J., Nov. 19, 2012 /PRNewswire/ -- Validus Pharmaceuticals together with Wood Creek Capital Management, LLC announced today the acquisition of the U.S. rights to six well-known product lines from Novartis Pharmaceuticals Corporation (NPC): Lopressor® (metoprolol tartrate USP) but excluding Lopressor (metoprolol tartrate) Injection, Lopressor® HCT (metoprolol tartrate USP + hydrochlorothiazide USP), Lotensin® (benazepril HCl), Lotensin HCT® (benazepril HCl + hydrochlorothiazide USP), Parlodel® (bromocriptine mesylate USP) and Methergine® (methylergonovine maleate).

Wood Creek Capital Management acquired the NPC products on August 29, 2012 through a new company, US Pharmaceuticals Holdings I LLC. Validus Pharmaceuticals will serve as the exclusive manager for the ex-NPC lines. These products present Validus with opportunities to generate sales in several new therapeutic markets and represent a significant growth catalyst for the company.

"The management and marketing of these significant new product lines fulfills a major step in Validus Pharmaceuticals' strategic plan for continued growth," commented James Hunter, Validus CEO. "The company's life-cycle plan had called for the timely expansion of product offerings beyond our successful Central Nervous System and Renal product lines. Adding these Novartis-developed medications immediately enables Validus to serve additional large and growing markets, particularly Cardiovascular Health."

"The acquisition of U.S. rights to these Novartis Pharmaceuticals Corporation products illustrates our belief in and commitment to the mature branded pharmaceuticals market," says Brett Hellerman, Wood Creek CEO.  "This is another in a series of successful transactions completed with large pharmaceutical companies that demonstrates we are good deal partners.  We are excited about the potential for our strategy."

As manufacturing of these products transitions to Validus, the company is working rapidly in order to assure both physicians and patients of a continued product supply under their label. Validus will be communicating directly with distributors and prescribing physicians regarding the availability of all these products.

About Validus Pharmaceuticals
Validus Pharmaceuticals LLC is a Parsippany, New Jersey-based specialty pharmaceutical company focused on the acquisition, reformulation, and marketing of FDA-approved prescription products that satisfy unmet clinical needs.  To fulfill this mission, Validus seeks out and acquires marketed products that have well established safety profiles as well as significant clinical benefits. 

For additional information please visit www.validuspharma.com.

About Wood Creek Capital Management, LLC

Wood Creek Capital Management is an investment manager at the forefront of private assets investing.  Headquartered in New Haven, CT Wood Creek has $930 million of committed capital under management as of June 30, 2012.  Wood Creek is a leading investor in intangible assets including pharmaceutical brands. 

For additional information please visit www.woodcreekcap.com.


'/>"/>
SOURCE Validus Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... YORK , Jan. 19, 2017 This ... the current and future scenario of the global market. ... rising opioid consumption. Severe chronic constipation is a major ... to traditional laxatives. Hence, novel targeted therapy has been ... OIC sufferers, launch of targeted medicines, and growing awareness ...
(Date:1/19/2017)... 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ), ... dysfunction, today announced new additions to its senior leadership ... Medical Officer, and Daniel Geffken as interim ... Jim Carr , Pharm.D. has been promoted to Chief ... to welcome Doug and Daniel to our management team, ...
(Date:1/19/2017)... January 19, 2017 According to a study ... is set to witness a CAGR of 6.5% during the forecast ... will continue to be the leading market for cryotherapy globally ... ... emphasizing on ensuring affordable and adequate supply of gas in order ...
Breaking Medicine Technology:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... International Protein, ... nutritional and bodybuilding supplements, announced it attended the January ECRM trade show in Hilton ... and nutritional scientist who was determined to create a line of products that would ...
(Date:1/20/2017)... ... , ... “Mary Magdalene: Grace is Greater than Sin”: a unique and ... Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the creation of published ... with countless women who had little knowledge of the female characters portrayed in the ...
(Date:1/20/2017)... Farmville, NC (PRWEB) , ... January 20, 2017 ... ... the vPEP ® Oscillating Positive Expiratory Pressure (OPEP) device, was featured in ... article by Doug Pursley, MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive ...
(Date:1/20/2017)... ... 20, 2017 , ... “The Land of More and More”: a brilliant ... hunger, and shares the simple and achievable answer. “The Land of More and More” ... Fairview Missionary Church in Angola, Indiana where he works with the children’s ministry department. ...
(Date:1/19/2017)... ... 19, 2017 , ... Next week after January 20th, the fear for many ... that circumvent health needs of over 30 million. Many interviews with Dr. Carol Francis ... government public servants were suppose to prioritize. Interviews provided below. , Among ...
Breaking Medicine News(10 mins):